Regeneron Pharmaceuticals, Inc. (BIT:1REGN)
Italy · Delayed Price · Currency is EUR | Market Cap | 57.90B +23.1% |
| Revenue (ttm) | 12.94B +5.9% |
| Net Income | 3.84B -1.7% |
| EPS | 35.61 +4.1% |
| Shares Out | n/a |
| PE Ratio | 15.09 |
| Forward PE | 12.53 |
| Dividend | 3.11 (0.55%) |
| Ex-Dividend Date | May 19, 2026 |
| Volume | 3 |
| Open | 585.00 |
| Previous Close | 563.00 |
| Day's Range | 585.00 - 585.00 |
| 52-Week Range | 458.50 - 697.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial numbers in USD Financial StatementsNews
Regeneron price target lowered to $769 from $778 at Truist
Truist lowered the firm’s price target on Regeneron (REGN) to $769 from $778 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…
Regeneron price target lowered to $696 from $707 at RBC Capital
RBC Capital lowered the firm’s price target on Regeneron (REGN) to $696 from $707 and keeps a Sector Perform rating on the shares as part of a broader research note…
Regeneron price target lowered to $800 from $990 at HSBC
HSBC lowered the firm’s price target on Regeneron (REGN) to $800 from $990 and keeps a Buy rating on the shares. In a sector note on Healthcare, HSBC adjusted target…
Regeneron price target lowered to $750 from $785 at Cantor Fitzgerald
Cantor Fitzgerald analyst Carter Gould lowered the firm’s price target on Regeneron (REGN) to $750 from $785 and keeps an Overweight rating on the shares. Large-cap biopharmas are expected to…
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
The U.S. Food and Drug Administration has selected Eli Lilly and Regeneron , among seven companies, for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing fa...
Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says
Eli Lilly (LLY), Regeneron (REGN), Amneal (AMRX), Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA’s PreCheck pilot progr...
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA's PreCheck pilot program. The FDA PreCheck...
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursda...
Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital
RBC Capital keeps a Sector Perform rating and a $707 price target on Regeneron (REGN) but notes that the acquisition of Apogee Therapeutics (APGE) by AbbVie (ABBV) announced this morning…
Regeneron announces FDA, EMA accept cemdisiran submissions for review
Regeneron (REGN) announced that both the FDA and European Medicines Agency, or EMA, have accepted the regulatory applications for cemdisiran to treat adult patients with generalized myasthenia gravis,...
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing
Regeneron Pharmaceuticals Transcript: AGM 2026
The meeting approved all board proposals, including director elections, auditor ratification, and executive compensation. Strong financial growth was reported, with significant R&D investment and pipeline expansion highlighted. No shareholder questions were submitted.
Regeneron Pharmaceuticals Slides: FY 2026
Regeneron Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 12, 2026.
Regeneron Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Strong Q1 growth was driven by core franchises, with EYLEA HD and DUPIXENT showing momentum. The pipeline remains robust, with key catalysts expected in the second half, including regulatory and clinical milestones. Strategic flexibility in M&A and collaborations, plus a focus on IP protection and next-generation assets, position the company for long-term growth.
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare...
CytomX Therapeutics expands licensing agreement with Regeneron
CytomX Therapeutics (CTMX) announced an expansion of its collaboration and licensing agreement with Regeneron Pharmaceuticals (REGN) to create conditionally-activated bispecific cancer therapies utili...
Regeneron Ebola antibody recommended by WHO for investigational use
Regeneron (REGN) announced that maftivimab, the most potent neutralizing antibody included in Inmazeb, has been recommended by the World Health Organization’s, or WHO, Therapeutics Advisory Group to b...
Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
Inmazeb ® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically ...
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)
Philadelphia, Pennsylvania--(Newsfile Corp. - May 25, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The investigation c...
Regeneron says EMA accepted review under AA the MAA for Otarmeni
Regeneron (REGN) Pharmaceuticals announced the European Medicines Agency, EMA, has accepted for review under Accelerated Assessment, AA, the Marketing Authorization Application, MAA, for Otarmeni, an ...
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessmen...
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
Normalization of free light chains occurred by day 15 across all doses 100% of patients achieved a hematologic complete response (CR) at the highest tested dose Majority of patients with renal or card...
Regeneron price target lowered to $875 from $1,057 at Canaccord
Canaccord analyst John Newman lowered the firm’s price target on Regeneron (REGN) to $875 from $1,057 and keeps a Buy rating on the shares. The firm updated its model following…
Regeneron stock drops double digits on oncology trial failure
Shares of Regeneron Pharmaceuticals (REGN) fell about 12% on Monday, making the biotech company the worst-performing stock in the S&P 500 after its experimental melanoma treatment failed a pivotal lat...
Regeneron price target lowered to $860 from $900 at Wolfe Research
Wolfe Research analyst Alexandria Hammond lowered the firm’s price target on Regeneron (REGN) to $860 from $900 and keeps an Outperform rating on the shares. The company’s LAG-3 trial missed…